362 results about "Sapogenin" patented technology

The present invention is directed to novel compositions of bio-active compounds comprising 4-hydroxyisoleucine and one or more compounds selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compositions of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, proline, lysine, histidine, and gamma-aminobutyrate. The composition of bio-active compounds preferably include between about ten percent and about seventy percent of 4-hydroxyisoleucine and between about twenty percent and about forty percent of other amino acids. The bio-active compounds of the novel composition of the present invention may be derived, isolated, and/or extracted from Fenugreek seeds. A preferred method for extracting the bio-active compounds from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bio-active compounds from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compositions of bio-active compounds have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.

The invention relates to a hederagenin and a preparation method and purposes thereof. The compound is that the hederagenin is distilled from Nigella glandulifera freyn by degreasing, leaching and macroporous resin absorption, a structure of the hederagenin is confirmed by using physico-chemical constants, spectra database and single crystal method of X-ray diffractometry, the distilled hederagenin is proved in vitro to have the effect of tyrosine protein phosphatase PTP1B retardant and purposes as anti-diabetes drugs and health care products, meanwhile, the hederagenin is also applicable to be combination of drugs made from the compound or derivatives of the compound.

Improved methods and compositions for protecting plants or seeds from plant diseases are provided. The compositions comprise (and preferably consist essentially of) saponin, such as triterpene type saponins extracted from quinoa or quillaja. Compositions according to the invention may comprise (or consist essentially of) a quantity of a sapogenin compound, preferably a sapogenins selected from the group consisting of oleanolic acid, hederagenin, phytolaccinic acid, and quillaic acid. The methods comprise contacting the portion of the plant (e.g., foliage, shoot, etc.) to be treated with a disease-inhibiting or protective amount of the composition. The compositions can also be used to treat plant seeds or tubers prior to planting thereof, as well as soil adjacent a growing plant. The inventive compositions are particularly useful for the treatment, control and/or prevention of bacterial diseases. The saponins of the invention can be applied as liquids or dry particulates, and are especially suited for the treatment of tomato and potato plants and their respective seeds.

This invention refers to 17alpha ,22 - dihydroxy Furan Steride compounds and its application. The compound' s structure formula is drawing in right graph, wherein the R1, R2 and R3 = H, C1-10 direct chain, cyclane group or alkenyl , triethylsilyl, dimethyl- tert-butylsilyl-biphenyl-tert-butylsilyl, methoxymethyl or tetrahydropyranyl. R4 = H see right formula a, b, C1-10 direct chain, cyclane group, alkenyl or alkynyl , R5 = C1-10 direct chain or cyclane group, R6 = H, C1-10 direct chain or cyclane group or alkenyl, triethylsilyl, dimethyl- tert-butylsilyl, biphenyl-tert-butylsilyl, methoxymethyl, tetrahydropyranyl. The start materials is diosgenin, which is easy available and cheap. Through F-cyclic degrading, the degradation product' s structure is converted into 17alpha,22 - dihydroxy furan steride compound. The compound again with F-cyclic restructure becomes the sapogenin, which is medicinal value. The process thereof is simple, adapted for industrialized production. It's glycoside of medicinal herbs Chonglou (Paris petiolata bak) sapogenin as one active ingredient, whose synthesis is provided herewith is effectively.

The present invention discloses the composition, extraction process and use of total triterpene sapogenin extracted from bamboo. The triterpene sapogenin is extracted from stem, branch, leaf, root, shoot, etc. of bamboo as one kind of gramineous plant via supercritical CO2 fluid extraction process. The test via vanillin-perchloric acid colorimetry method and GC-MS method shows that the extractive has total triterpene sapogenin content of 10-90 %, friedelin content of 5-35 % and lupenone content of 1-10 %. The extractive as one mixture of five-cycle triterpene compounds (EZR2002) has excellent physiological and pharmacological activity of resisting free radical, resisting oxidation, resisting tumor, lowering blood pressure, etc. and may be used in medicine and health care article for preventing and treating cardiac and cerebral vascular diseases and resisting tumor and may be also used in cosmetics.

The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.

The invention provides a structure and a synthetic method thereof. The structure is obtained by modifying structures such as yam steroid sapogenin, proluton, dehydroepihydro-ketone and the like, and has an endothelin receptor A antagonistic active compound.

The invention relates to novel diosgenin piperazine compounds, a preparation method thereof and application of a medicinal composition taking the compounds as active ingredients in antitumor aspects. The preparation method comprises the steps of: preparing 1-sterides piperazine compounds from diosgenin and piperazine serving as raw materials; and reacting the 1-sterides piperazine compound with ArX to synthesize a series of 1-sterides-4-substituted piperazine compounds, wherein the 1-sterides-4-substituted piperazine compounds are expressed by general formulas (I) and (II). Pharmacological tests prove that the diosgenin piperazine compounds have the obvious inhibitory action on A375, A549 and HepG-2 cell strains, and are superior to diosgenin.

The invention relates to a kind of natural cleaning dew. The characteristic of the invention is that all the materials of the cleaning dew are from nature, so the product is totally worthy of the name 'pure natural cleaning dew'. The betaine, tea sapogenin and coconut oil derivates are natural active compounds which have good quality of deoiling and decontaminating; the protease can remove the pesticide residue; the rice vinegar can sterilize different things; lemon essence can add incense and protect skin; the extracts of the traditional Chinese medicine have the function of heat-clearing and detoxicating, killing parasites to relieve itching, enriching skins and hair. Combining the previous ingredients scientifically can get different kinds of cleaning products to satisfy varied needs of customers, such as cleaning vegetables, eating apparatus and cookers or cleaning hands, hair and bodies.

The invention discloses a bulk drug for treating orthopaedic diseases. The bulk drug is Chinese teasel root saponin VI and is prepared by extracting traditional Chinese medicinal materials which contain the Chinese teasel root saponin VI; the weight percentage content of the Chinese teasel root saponin VI occupies 95.0 to 99.9 percent of the total amount of an extract of the Chinese teasel root saponin VI; and the chemical name of the bulk drug is 3-O-alpha-L-arabopyranose ivy sapogenin-28-O-beta-D-glucopyranose(1-6)-beta-D-glucopyranoside. The invention also discloses a method for preparing the bulk drug - the Chinese teasel root saponin VI. The method comprises the following steps of extraction, concentration, separation of the total saponin, decolorization and purification and refinement. The preparation method has the advantages that the preparation method has high extraction rate and low cost, is safe and environment-friendly and is suitable for industrialized mass production. The invention also provides application of the bulk drug in preparing medicines for preventing and treating the orthopaedic diseases including osteoporosis, fracture and osteoarthritis.

The invention relates to a ginseng stem leaf total sapogenin oral pharmaceutical preparation as well as a preparation method and an application thereof, belonging to the field of traditional Chinese medicines. Total aglycone extracted from ginseng stem leaf is hydrolyzed to obtain ginseng stem leaf total sapogenin, and the ginseng stem leaf total sapogenin is made into an efficient preparation by matching with a special auxiliary material, thereby the bioavailability of the ginseng stem leaf total sapogenin can be greatly improved. The preparation has obvious curative effect in the aspect of curing diseases such as coronary heart disease, stenocardia, miocardial infarction, hepatitis, tumour, pulmonary heart disease, high blood pressure, and the like or the aspect of preventing depressive illness and senile-resistant.

An application of ruscorectal and/or its heteroside prepared from ruscorectal and saccharide chain in preparing the medicine for preventing and treating thrombotic diseases is disclosed.

The present invention is directed to novel compositions of bio-active compounds comprising 4-hydroxyisoleucine and one or more compounds selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compositions of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, proline, lysine, histidine, and gamma-aminobutyrate. The composition of bio-active compounds preferably include between about ten percent and about seventy percent of 4-hydroxyisoleucine and between about twenty percent and about forty percent of other amino acids. The bio-active compounds of the novel composition of the present invention may be derived, isolated, and/or extracted from Fenugreek seeds. A preferred method for extracting the bio-active compounds from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bio-active compounds from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compositions of bio-active compounds have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.

The invention discloses a method for preparing the laxogenin sapogenin from the smilax scobinicaulis plants. The smilax scobinicaulis is extracted by utilizing the solvents and the extracts are dissolved in the water; then the obtained solutions are subject to the extraction using the weak-polarity and moderate-polarity organic solvents and water-immiscible C<4-10> lower alcohol solvents in order so as to obtain the extracts. The pure sapogenin is obtained in two ways that: one is to take the weak-polarity or moderate-polarity solvent extracts into the separation by the non-polar or weak-polar macroporous resin and obtain the laxogenin sapogenin by taking the isolates into the Sephadex LH-20 purification and drying the obtained mixtures; the other is carried out in the way that the lower alcohol extrats are taken and the total saponins are prepared through the weak-polar or polar macroporous resin; the diluted acids are added in the total saponins so as to carry out the hydrolysis and then the obtained solution is extracted using the weak-polarity solvents and the laxogenin sapogenin is obtained by drying the extracts. The method for preparing the laxogenin sapogenin has a simple process, delivers an easy-to-master technology, has small energy consumptions, high extraction rate, excenllent purity equotient of laxogenin sapogenin and low production cost, and provides raw materials for developing the drugs for treating the cardiovascular diseases and antitumor drugs, plant hormone products and chemical synthesis.

This invention relates to a group of novel sapogenins, their use in anti-cancer applications, and to a process for their production. More particularly, this invention pertains to a novel group of dammarane sapogenins, PAM-120, PBM-110 and PBM-100 (the dammarance sapogenine structure is specifically clean of any sugar moieties (glycons) at any position and hydroxyl at C-20) and PAN-20 and PAN-30 (the dammarance sapogenin structure has sugar moieties but is free of hydroxyl at C-20), obtained by chemical cleavage of dammarane saponins. The invention also includes a novel application of the said sapogenins for anti-cancer treatment by using them separately or together, and/or jointly with other drugs, as well as to the process of producing these novel sapogenins. Said novel dammarane sapogenins show surprising anti-cancer effect when applied, particularly against multi-drug resistant cancers.

This invention relates to a method of taking tea oil residue as raw material to extract tea saponin and tea polyose. The preparation process includes: preparation of extract, dissolution of normal butyl alcohol and separating of solid; solid once again dissolve in higher temperature anhydrous normal butyl alcohol, cooling, filtration, gain tea saponin; reclaim normal butyl alcohol solution, gain hybrid containing tea polyose; add hydrous ethanol to the hybrid, the insoluble substance is tea polyose product. This invention has merits of simple craft, low cost and high yield, and low environmental pollution. The product purity is high , tea saponin is white, tea polyose is white.